MedMira Inc. (MMIRF)
USD 0.02
(-70.43%)
USD 0.02
(-70.43%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.94 Million CAD | -33.79% |
| 2022 | -1.45 Million CAD | -688.8% |
| 2021 | -184.23 Thousand CAD | 85.83% |
| 2020 | -1.3 Million CAD | -0.32% |
| 2019 | -1.29 Million CAD | 29.57% |
| 2018 | -1.84 Million CAD | 13.73% |
| 2017 | -2.13 Million CAD | 52.37% |
| 2016 | -4.47 Million CAD | -81.22% |
| 2015 | -2.47 Million CAD | 30.74% |
| 2014 | -3.56 Million CAD | -64.8% |
| 2013 | -2.16 Million CAD | -0.23% |
| 2012 | -2.16 Million CAD | -16.34% |
| 2011 | -1.85 Million CAD | 20.55% |
| 2010 | -2.33 Million CAD | 7.49% |
| 2009 | -2.52 Million CAD | 22.22% |
| 2008 | -3.24 Million CAD | 9.01% |
| 2007 | -3.57 Million CAD | 34.83% |
| 2006 | -5.47 Million CAD | -23.18% |
| 2005 | -4.44 Million CAD | -27.27% |
| 2004 | -3.49 Million CAD | 18.93% |
| 2003 | -4.31 Million CAD | 15.69% |
| 2002 | -5.11 Million CAD | 23.7% |
| 2001 | -6.7 Million CAD | -102.62% |
| 2000 | -3.3 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -656.81 Thousand CAD | -12.45% |
| 2024 Q2 | -536.32 Thousand CAD | 10.33% |
| 2024 Q1 | -598.09 Thousand CAD | -34.64% |
| 2023 Q1 | -497.88 Thousand CAD | -21.83% |
| 2023 FY | -1.94 Million CAD | -33.79% |
| 2023 Q2 | -369.8 Thousand CAD | 25.72% |
| 2023 Q3 | -632.41 Thousand CAD | -71.01% |
| 2023 Q4 | -444.2 Thousand CAD | 29.76% |
| 2022 Q4 | -408.68 Thousand CAD | -38.12% |
| 2022 Q3 | -295.89 Thousand CAD | 17.72% |
| 2022 FY | -1.45 Million CAD | -688.8% |
| 2022 Q1 | -389.03 Thousand CAD | 36.4% |
| 2022 Q2 | -359.61 Thousand CAD | 7.56% |
| 2021 Q3 | -197.46 Thousand CAD | 23.58% |
| 2021 Q1 | 883.35 Thousand CAD | 1810.33% |
| 2021 Q2 | -258.39 Thousand CAD | -129.25% |
| 2021 FY | -184.23 Thousand CAD | 85.83% |
| 2021 Q4 | -611.72 Thousand CAD | -209.79% |
| 2020 Q1 | -283.3 Thousand CAD | 7.62% |
| 2020 Q3 | -532.65 Thousand CAD | -23.14% |
| 2020 Q2 | -432.54 Thousand CAD | -52.68% |
| 2020 FY | -1.3 Million CAD | -0.32% |
| 2020 Q4 | -51.64 Thousand CAD | 90.3% |
| 2019 FY | -1.29 Million CAD | 29.57% |
| 2019 Q1 | -306.72 Thousand CAD | 4.6% |
| 2019 Q2 | -373.3 Thousand CAD | -21.7% |
| 2019 Q3 | -309.31 Thousand CAD | 17.14% |
| 2019 Q4 | -306.68 Thousand CAD | 0.85% |
| 2018 Q1 | -467.25 Thousand CAD | -25.75% |
| 2018 FY | -1.84 Million CAD | 13.73% |
| 2018 Q4 | -321.51 Thousand CAD | 37.2% |
| 2018 Q3 | -511.93 Thousand CAD | 5.13% |
| 2018 Q2 | -539.59 Thousand CAD | -15.48% |
| 2017 Q2 | -428.87 Thousand CAD | 39.38% |
| 2017 FY | -2.13 Million CAD | 52.37% |
| 2017 Q4 | -371.58 Thousand CAD | 40.57% |
| 2017 Q3 | -625.22 Thousand CAD | -45.78% |
| 2017 Q1 | -707.47 Thousand CAD | 63.01% |
| 2016 Q1 | -709.93 Thousand CAD | -531.43% |
| 2016 FY | -4.47 Million CAD | -81.22% |
| 2016 Q2 | -815.43 Thousand CAD | -14.86% |
| 2016 Q3 | -1.04 Million CAD | -27.66% |
| 2016 Q4 | -1.91 Million CAD | -83.73% |
| 2015 Q4 | -112.43 Thousand CAD | 83.29% |
| 2015 Q3 | -672.99 Thousand CAD | 28.48% |
| 2015 FY | -2.47 Million CAD | 30.74% |
| 2015 Q2 | -940.96 Thousand CAD | -26.29% |
| 2015 Q1 | -745.07 Thousand CAD | 9.5% |
| 2014 Q4 | -823.28 Thousand CAD | 17.87% |
| 2014 FY | -3.56 Million CAD | -64.8% |
| 2014 Q3 | -1 Million CAD | 13.28% |
| 2014 Q1 | -586.95 Thousand CAD | -44.78% |
| 2014 Q2 | -1.15 Million CAD | -96.94% |
| 2013 Q4 | -405.4 Thousand CAD | 44.58% |
| 2013 Q2 | -554.81 Thousand CAD | -17.15% |
| 2013 Q1 | -473.57 Thousand CAD | 21.29% |
| 2013 Q3 | -731.57 Thousand CAD | -31.86% |
| 2013 FY | -2.16 Million CAD | -0.23% |
| 2012 FY | -2.16 Million CAD | -16.34% |
| 2012 Q1 | -537.28 Thousand CAD | -34.99% |
| 2012 Q2 | -1.07 Million CAD | -99.69% |
| 2012 Q4 | -601.66 Thousand CAD | -9.81% |
| 2012 Q3 | -547.9 Thousand CAD | 48.93% |
| 2011 Q4 | -398.02 Thousand CAD | -3.07% |
| 2011 FY | -1.85 Million CAD | 20.55% |
| 2011 Q2 | -623.03 Thousand CAD | -38.48% |
| 2011 Q1 | -449.89 Thousand CAD | 56.84% |
| 2011 Q3 | -386.15 Thousand CAD | 38.02% |
| 2010 FY | -2.33 Million CAD | 7.49% |
| 2010 Q4 | -1.04 Million CAD | -322.15% |
| 2010 Q3 | -246.91 Thousand CAD | 53.01% |
| 2010 Q2 | -525.48 Thousand CAD | -0.56% |
| 2010 Q1 | -522.56 Thousand CAD | 36.17% |
| 2009 Q3 | -474.51 Thousand CAD | 30.79% |
| 2009 Q2 | -685.63 Thousand CAD | -25.16% |
| 2009 Q1 | -547.81 Thousand CAD | 43.25% |
| 2009 FY | -2.52 Million CAD | 22.22% |
| 2009 Q4 | -818.68 Thousand CAD | -72.53% |
| 2008 Q1 | -745.62 Thousand CAD | 23.0% |
| 2008 FY | -3.24 Million CAD | 9.01% |
| 2008 Q4 | -965.34 Thousand CAD | -17.49% |
| 2008 Q3 | -821.66 Thousand CAD | -49.47% |
| 2008 Q2 | -549.72 Thousand CAD | 26.27% |
| 2007 Q4 | -968.33 Thousand CAD | -67.0% |
| 2007 Q2 | -978 Thousand CAD | 6.35% |
| 2007 FY | -3.57 Million CAD | 34.83% |
| 2007 Q3 | -579.84 Thousand CAD | 40.71% |
| 2007 Q1 | -1.04 Million CAD | 41.12% |
| 2006 Q3 | -1.73 Million CAD | -149.86% |
| 2006 Q4 | -1.77 Million CAD | -1.96% |
| 2006 FY | -5.47 Million CAD | -23.18% |
| 2006 Q1 | -1.26 Million CAD | 12.38% |
| 2006 Q2 | -696.25 Thousand CAD | 45.13% |
| 2005 Q1 | -890.1 Thousand CAD | -34.21% |
| 2005 Q2 | -1.07 Million CAD | -21.24% |
| 2005 Q3 | -1.03 Million CAD | 4.53% |
| 2005 Q4 | -1.44 Million CAD | -40.55% |
| 2005 FY | -4.44 Million CAD | -27.27% |
| 2004 Q2 | -963.65 Thousand CAD | -10.83% |
| 2004 Q4 | -663.2 Thousand CAD | 33.56% |
| 2004 FY | -3.49 Million CAD | 18.93% |
| 2004 Q1 | -869.45 Thousand CAD | -14.02% |
| 2004 Q3 | -998.14 Thousand CAD | -3.58% |
| 2003 Q2 | -1.03 Million CAD | -9.84% |
| 2003 Q4 | -762.56 Thousand CAD | 51.65% |
| 2003 Q3 | -1.57 Million CAD | -52.95% |
| 2003 FY | -4.31 Million CAD | 15.69% |
| 2003 Q1 | -938.88 Thousand CAD | 53.4% |
| 2002 Q2 | -858.48 Thousand CAD | 29.15% |
| 2002 Q1 | -1.21 Million CAD | 0.0% |
| 2002 FY | -5.11 Million CAD | 23.7% |
| 2002 Q3 | -1.02 Million CAD | -19.7% |
| 2002 Q4 | -2.01 Million CAD | -96.06% |
| 2001 FY | -6.7 Million CAD | -102.62% |
| 2000 FY | -3.3 Million CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -1.25 Million USD | -54.802% |
| Skye Bioscience, Inc. | -13.67 Million USD | 85.779% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 102.375% |
| Nascent Biotech, Inc. | -2.22 Million USD | 12.806% |
| Qrons Inc. | -643.67 Thousand USD | -202.064% |
| Adynxx, Inc. | - USD | Infinity% |
| BioStem Technologies, Inc. | -7.77 Million USD | 75.005% |
| CSL Limited | 3.7 Billion USD | 100.053% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 89.106% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 61.457% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -183.036% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 96.497% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -367.97% |
| Rebus Holdings, Inc. | -664 Thousand USD | -192.819% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -45.595% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -399.093% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 87.748% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 97.292% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 139.56% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -642.883% |
| SQZ Biotechnologies Company | -75.82 Million USD | 97.436% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 31.79% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -26.579% |
| Mesoblast Limited | -84.14 Million USD | 97.689% |
| Marizyme, Inc. | -34.08 Million USD | 94.296% |
| Genus plc | 6.4 Million USD | 130.38% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 119.957% |
| Pharming Group N.V. | -4.87 Million USD | 60.154% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | 2.122% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -108.757% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 76.715% |
| ContraFect Corporation | -56.88 Million USD | 96.582% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 57.312% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -38.683% |
| IMV Inc. | -38.67 Million USD | 94.972% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 29.319% |
| MultiCell Technologies, Inc. | -722.81 USD | -268894.342% |
| ONE Bio Corp. | 13.68 Million USD | 114.211% |
| Accustem Sciences Inc. | -3.74 Million USD | 48.102% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 96.704% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -302.499% |
| Q BioMed Inc. | -3.44 Million USD | 43.571% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 154.924% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 26.002% |
| Biomind Labs Inc. | -1 Million USD | -92.582% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 96.463% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 32.983% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 70.753% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -4.288% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -6391.446% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -0.606% |
| GB Sciences, Inc. | -1.42 Million USD | -36.875% |
| Alpha Cognition Inc. | -9.7 Million USD | 79.967% |
| HST Global, Inc. | -140.9 Thousand USD | -1279.859% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -72.843% |
| Halberd Corporation | -75.05 Thousand USD | -2490.697% |
| Enzolytics Inc. | -2.14 Million USD | 9.516% |
| Agentix Corp. | -1.37 Million USD | -41.739% |
| Resverlogix Corp. | -12.74 Million USD | 84.749% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 38.632% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.543% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -86.237% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 33.401% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -23.108% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 42.898% |
| AVAX Technologies, Inc. | 6.69 Million USD | 129.051% |
| Zenith Capital Corp. | -8.94 Million USD | 78.259% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.532% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -11060.771% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | 20.812% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1033.65% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 3.015% |
| Kadimastem Ltd | -3.04 Million USD | 36.047% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -97.583% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -971.338% |
| LadRx Corporation | -3.82 Million USD | 49.15% |
| Cell Source, Inc. | -4.32 Million USD | 55.048% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -183.036% |
| NovAccess Global Inc. | -2.46 Million USD | 21.179% |
| Affymax, Inc. | -15.04 Million USD | 87.078% |
| Itoco Inc. | -919.14 Thousand USD | -111.537% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 54.126% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -73.755% |
| Mobile Lads Corp. | -554.55 Thousand USD | -250.612% |
| CytoDyn Inc. | -18.05 Million USD | 89.233% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -7624.744% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -783.468% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -244.296% |
| SYBLEU INC | -149.18 Thousand USD | -1203.337% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -7.047% |
| International Stem Cell Corporation | -663 Thousand USD | -193.261% |
| Bioxytran, Inc. | -3.82 Million USD | 49.104% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -3593.613% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -9459.086% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 94.639% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -20.168% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -164.233% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 37.502% |
| Neutra Corp. | -229.48 Thousand USD | -747.249% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 88.914% |
| PureTech Health plc | -146.19 Million USD | 98.67% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 90.953% |
| IXICO plc | -1.43 Million USD | -35.304% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 79.514% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 98.404% |
| CSL Limited | 3.81 Billion USD | 100.051% |
| Cellectis S.A. | -108.85 Million USD | 98.214% |